Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
- Conditions
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 16
- Registration Number
- NCT00384150
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 340
- Registration Number
- NCT00363636
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 70
- Registration Number
- NCT00345189
- Locations
- 🇬🇧
Research site, Sutton, Surrey, United Kingdom
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2009-06-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 15
- Registration Number
- NCT00344786
- Locations
- 🇺🇸
Research Site, San Diego, California, United States
🇺🇸Research site, Houston, Texas, United States
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 10
- Registration Number
- NCT00319930
Natalizumab Re-Initiation of Dosing
- Conditions
- Interventions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 404
- Registration Number
- NCT00306592
- Locations
- 🇨🇦
Research Center, New York, Ontario, Canada
🇨🇦Research Site, Montreal, Quebec, Canada
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 54
- Registration Number
- NCT00298272
- Locations
- 🇺🇸
Research Site, Burlington, Vermont, United States
🇺🇸Research site, Chardon, Ohio, United States
Natalizumab (Tysabri) Re-Initiation of Dosing
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1094
- Registration Number
- NCT00297232
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2007-12-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 50
- Registration Number
- NCT00292422
- Locations
- 🇺🇸
Fiechtner Research Inc., Lansing, Michigan, United States
🇺🇸Arthritis Consultants Inc., St. Louis, Missouri, United States
🇵🇱Klinika Chorob Tkanki Lacznej-Instytut Reumatologiczny, Warsawa, Poland
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
- Conditions
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 300
- Registration Number
- NCT00288990
- Locations
- 🇺🇸
The Baptist Hospital of East Tennessee, Knoxville, Tennessee, United States
🇺🇸Neurology Center of Fairfax, Ltd., Fairfax, Virginia, United States
🇺🇸The Multiple Sclerosis Center at the Ohio State University, Columbus, Ohio, United States